Biloxi Marsh Lands Corp. (BLMC) Financials Nov 14, 2014,

New Post Public Reply Private Reply Replies (0) Message Board
Hirata
Biloxi Marsh Lands Corp. (BLMC) Financials Nov 14, 2014, 8:10 p.m.
Income Statement Balance Sheet Cash Flow Statement
Annual Financials for Biloxi Marsh Lands Corp.


Fiscal year is January-December. All values USD millions. 2009 2010 2011 2012 2013 5-year trend
Sales/Revenue 25.5M 7.62M 3.42M 572,559 2.93M
Cost of Goods Sold (COGS) incl. D&A 736,860 615,703 750,591 - 65,176
COGS excluding D&A 673,500 589,356 729,841 - 56,092
Depreciation & Amortization Expense 63,360 26,347 20,750 5,025 9,084
Depreciation 63,360 26,347 20,750 5,025 9,084
Amortization of Intangibles 0 0 0 0 -
Gross Income 24.77M 7M 2.67M - 2.86M
2009 2010 2011 2012 2013 5-year trend
SG&A Expense - - - 757,280 598,524
Research & Development - - - - -
Other SG&A - - - 757,280 598,524
Other Operating Expense 1.4M 1.03M 688,523 220,778 452,314
Unusual Expense 0 0 0 0 (3.19M)
EBIT after Unusual Expense 0 0 0 0 3.19M
Non Operating Income/Expense (2.49M) 218,149 0 141,318 0
Non-Operating Interest Income 0 - - 199,024 0
Equity in Affiliates (Pretax) 0 (764,018) (3.42M) (714,604) (1.74M)
Interest Expense 0 0 0 0 0
Gross Interest Expense 0 0 0 0 0
Interest Capitalized 0 0 0 0 0
Pretax Income 20.87M 5.42M (1.44M) (784,786) 3.26M
Income Tax 7.15M 1.49M (742,661) (324,151) 808,937
Income Tax - Current Domestic 7.15M 1.49M 71,146 (711,613) 403,857
Income Tax - Current Foreign - - - - -
Income Tax - Deferred Domestic - - (813,807) 387,462 405,080
Income Tax - Deferred Foreign - - - - -
Income Tax Credits 0 0 0 - 0
Equity in Affiliates 0 0 0 - 0
Other After Tax Income (Expense) 0 0 0 0 0
Consolidated Net Income 13.72M 3.93M (695,955) (460,635) 2.45M
Minority Interest Expense 0 0 0 0 0
Net Income 13.72M 3.93M (695,955) (460,635) 2.45M
Extraordinaries & Discontinued Operations 0 0 0 0 0
Extra Items & Gain/Loss Sale Of Assets 0 0 0 0 0
Cumulative Effect - Accounting Chg 0 0 0 0 0
Discontinued Operations 0 0 0 0 0
Net Income After Extraordinaries 13.72M 3.93M (695,955) (460,635) 2.45M
Preferred Dividends 0 0 0 0 0
Net Income Available to Common 13.72M 3.93M (695,955) (460,635) 2.45M
EPS (Basic) 5.00 1.44 (0.25) (0.17) 0.90
Basic Shares Outstanding 2.74M 2.73M 2.78M 2.72M 2.72M
EPS (Diluted) 5.00 1.44 (0.25) (0.17) 0.90
Diluted Shares Outstanding 2.74M 2.73M 2.78M 2.72M 2.72M
EBITDA 23.43M 5.99M 2.01M (405,499) 1.82M
Copyright 2014 FactSet Research Systems Inc. All rights reserved. Source FactSet Fundamentals.
Scroll down for more posts ▼

Top 10 Most Recent News Articles

AtWork Welcomes Franchise Vet Sarah Goehring

Updated Category News Views 17

A Strategic Move for AtWork There's a new heavyweight at AtWork, a name that's been catching attention in the franchise biz lately—Sarah Goehring. This isn't just another appointment; it's a signal flare for AtWork's ambitions. With Goehring, they're doubling down on scaling their operation and drawing in more franchise players who are ready to hit the ground running....

Continue Reading
Partner Valuation Advisors Bolsters Team with Eichman

Updated Category News Views 6

Eichman Joins Partner Valuation Advisors as MD Turns out the buzz in real estate appraisal isn’t just about property values these days; it's about who's valuing them. Just ask Partner Valuation Advisors, who are realigning their chess pieces by bringing seasoned pro Justin Eichman, MAI, on board as Managing Director. Talk about playing your cards right. A Heavyweight in...

Continue Reading
TechCrunch Disrupt 2026: NYSE and Snowflake Highlights

Updated Category News Views 20

Ever noticed how the air vibrates just a bit more when major players like NYSE and Snowflake start shaking hands at big-league events like TechCrunch Disrupt? You'd better believe we're seeing a fresh brew of opportunities and challenges in the market as these titans lock horns and share insights. It's no small feat when the financial nerve center partners into the tech...

Continue Reading
Maven Pet's AI Paw-tnership: Changing Pet Care Landscape

Updated Category News Views 8

AI in the World of Doggie Docs In today's tech-driven world, pet owners are turning to artificial intelligence like never before. Forget flipping through outdated dog-care books—nearly half of us are drilling ChatGPT for health tips on our four-legged pals. Yes, it seems we’re asking an AI about Rover's health more than some other major life decisions. But let's face...

Continue Reading
Franco-Nevada's Q3 Results Loom: Investors Ready

Updated Category News Views 15

Gearing Up: Franco-Nevada's Q3 Numbers on the Horizon You know the drill! Franco-Nevada's third quarter results won't just trickle in—they'll set the tone for the months ahead. Mark your calendar: November 11th after the market closes is the magic hour when you'll get the skinny on their Q3 performance. The next morning, bright and early at 8:00 AM ET, they'll hash it...

Continue Reading
CMC Declares Dividend Amid Complex Outlook

Updated Category News Views 17

Dividend's Not Just a Regular Check October 13, 2026, marks yet another dividend declaration by CMC. This time, they're dishing out $0.20 per share—a steady payday for loyal shareholders. That's 248 times in a row they've done this song and dance. Odds are, folks holding NYSE:CMC shares are giving the nod of approval, but it ain't just about cash; it's about stability...

Continue Reading
Paradigm Therapeutics: A Beacon in Rare Diseases

Updated Category News Views 2

A Step Towards Recognition You know the old saying: innovation never sleeps. Well, Paradigm Therapeutics seems to have taken that to heart. The company's embarked on a peculiar yet promising journey with SD-101 (Zorblesia™), and here they are, basking in the glow of another nomination for the 2026 Prix Galien USA "Best Start-Up" award. It’s their second shot at this...

Continue Reading
New Data on SKYRIZI Offers Hope for Crohn's Patients

Updated Category News Views 12

Treating Crohn's: New Hope on the Horizon Folks, let me tell you, the landscape for treating Crohn's disease just got a bit more interesting. AbbVie's Phase 3 AFFIRM study has brought some attention-grabbing data on the table, showcasing the potential of their drug, SKYRIZI® (risankizumab-rzaa). This ain't just another run-of-the-mill study; these results could be a...

Continue Reading
Laars Welcomes Women in Manufacturing to Facility Tour

Updated Category News Views 6

Opening Doors and Minds in Manufacturing On October 15, Laars Heating Systems throws wide open its Rochester, N.H., facility to a group that's rewriting the rulebook: women in manufacturing. It's not just another day in the life of assembly lines and engineering desks, folks. This is about giving a platform to those often sidelined in the field of boilers and water...

Continue Reading
Home Buying: Unmasking All the Real Budget Costs

Updated Category News Views 2

Home Buying: More Costs Than Meets the Eye Let's face it, buying a home is no stroll in the park. It's a tangled web of numbers and surprises that can leave even the savviest buyer in a daze. Thank goodness for articles like the one from HelloNation featuring Serena LoPiccolo-Smith, which make the invisible visible when it comes to the financial intricacies of home...

Continue Reading
ore News Articles